Patent application number | Description | Published |
20110228630 | Reduced Transit Static Mixer Configuration - Excessive residence time in the conduits located between the outlet of a static mixer and a reactor/separator reservoir can lead to undesired by-products, formation of solids, and conduit fouling. This disclosure relates to an improved configuration for a static mixer with reduced transitory time to help reduce the creation of undesired by-products and fouling during the process of mixing, and more particularly to a phosgene reactor comprising a short or very short conduit for reducing the transit time from the static mixer to a reactor/separator reservoir to one second or less. | 09-22-2011 |
20110230679 | Reactive Static Mixer - This disclosure relates to a static phosgene mixer, and more generally, to an apparatus for mixing of fluid components such as phosgene and amine during an highly reactive, chemical reaction that is vulnerable to the creation of undesired by-products, and equipment fouling. A guide element is disposed in the static mixer to divert the incoming flow of phosgene around the guide element and create an annular mixing passage in the static mixer. This allows for the use of an increased external radius of the effective phosgene flow while maintaining phosgene velocity by creating a blockage of the flow. The same flow, when transformed from a circular configuration to an annular configuration has an increased external radius, and a greater quantity of MDA jets can be placed along the increased radius, thus increasing the overall homogeneity of the mixture. Further, the cross-sectional area of the annular passage section of phosgene defined around the guide element controls the velocity of phosgene which facilitates the mixing of MDA injected through the jets into the phosgene. | 09-22-2011 |
20110242930 | REACTIVE STATIC MIXER - This disclosure relates to a static phosgene mixer, and more generally, to an apparatus for mixing of fluid components such as phosgene and amine during an highly reactive, chemical reaction that is vulnerable to the creation of undesired by-products, and equipment fouling. A guide element is disposed in the static mixer to divert the incoming flow of phosgene around the guide element and create an annular mixing passage in the static mixer. This allows for the use of an increased external radius of the effective phosgene flow while maintaining phosgene velocity by creating a blockage of the flow. The same flow, when transformed from a circular configuration to an annular configuration has an increased external radius, and a greater quantity of MDA jets can be placed along the increased radius, thus increasing the overall homogeneity of the mixture. Further, the cross-sectional area of the annular passage section of phosgene defined around the guide element controls the velocity of phosgene which facilitates the mixing of MDA injected through the jets into the phosgene. | 10-06-2011 |
Patent application number | Description | Published |
20090029573 | Contact Device - A contact device is provided, the device having at least a first contact region for electrical connection to an electric line and at least a second contact region for electrical connection to a flexible printed circuit board other contact medium which may damaged by repeated soldering. The first contact region and the second contact region are electrically connected. Between the first contact region and the second contact region, a third region is provided which has a lower thermal conductivity per unit length than the first contact region and/or the second contact region. | 01-29-2009 |
20090061657 | HOLDER FOR A FLEXIBLE CIRCUIT BOARD - A holder with a device for holding a flexible circuit board is provided. The holder comprises at least one further device for holding at least one component such that the component may be electrically connected to or disconnected from the circuit board. | 03-05-2009 |
20100055967 | Electronic Module Having A Plug Connection - A module, particularly an electronic module of a commercial vehicle, includes at least one plug connection, having a plug element and a mating plug element, by which an electrical connection can be established when plugged together. At least one of the plug elements is mounted floatingly or movably within a clearance. A method for assembling the module plugs together the plug elements, at least one of the plug elements moving within a clearance relative to the mounting thereof. | 03-04-2010 |
20100068910 | SECURED PLUG CONNECTION AND METHOD FOR ITS PRODUCTION - A plug connection between electrical and/or electronic components, in which electrical plug contacts of a plug which is arranged directly adjacently to one component are inserted into a socket which is arranged directly adjacently to the other component, with the components being interlocked with one another by a connection arrangement or being combined to form an assembly, and in which a separate plug connection securing arrangement which is independent of the connection arrangement of the components is provided to secure the plug connection against movements of the plug relative to the socket and vice versa. | 03-18-2010 |
Patent application number | Description | Published |
20090291072 | MEANS AND METHODS FOR THE TREATMENT OF TUMOROUS DISEASES - Provided are pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject in the need thereof and the use of said bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia, whereby said construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention. | 11-26-2009 |
20100150918 | CROSS-SPECIES-SPECIFIC BINDING DOMAIN - The present invention relates to a polypeptide comprising a human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. In a further aspect the invention provides a method for the identification of polypeptides comprising a cross-species specific binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ε (CD3 epsilon). | 06-17-2010 |
20100183615 | CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS - The present invention relates to a polypeptide comprising a first human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. | 07-22-2010 |
20120244162 | CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS - The present invention relates to a polypeptide comprising a first human binding domain capbable of binding to an epitope of human and non-chimpanzee CD3ε (epsilon) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acid sequences encoding the polypeptide, to vectors comprising the nucleic acid sequences and to host cells comprising the nucleic acid sequences or vectors containing the nucleic acid sequences. In another aspect, the invention provides for a pharmaceutical composition comprising the polypeptide and methods of medical treatment or use of the polypeptide. | 09-27-2012 |
20130095103 | MEANS AND METHODS FOR THE TREAMENT OF TUMOROUS DISEASES - Provided are pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject in the need thereof and the use of said bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia, whereby said construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention. | 04-18-2013 |
Patent application number | Description | Published |
20110293619 | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY - The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain anti-body molecule. | 12-01-2011 |
20120034228 | CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY - The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an antigen selected from the group consisting of Prostate Stem Cell Antigen (PSCA), B-Lymphocyte antigen CD19 (CD19), hepatocyte growth factor receptor (C-MET), Endosialin, the EGF-like domain 1 of EpCAM, encoded by exon 2, Fibroblast activation protein alpha (FAP alpha) and Insulin-like growth factor I receptor (IGF-IR or IGF-1R). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule. | 02-09-2012 |
20130129730 | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY - The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule. | 05-23-2013 |
Patent application number | Description | Published |
20090150434 | Multiple Field Look Ahead and Value Help - Methods and apparatus, including computer program products, are provided for providing value help. In one aspect, there is provided a computer-implemented method. The method may include receiving, from a user interface, an input. Based on the received input, one or more fields may be determined from a plurality of columns of a table of a database. The determined one or more fields may be provided to the user interface for presentation as a value help to the input being presented at the user interface. Related apparatus, systems, methods, and articles are also described. | 06-11-2009 |
20140019889 | REGENERATING A USER INTERFACE AREA - A user interface (UI) area having multiple data sources is regenerated based upon changes made to UI elements associated with the UI area. To efficiently regenerate the changed UI elements, a processor of the computer determines UI controls and data objects associated with the UI area to generate a conditional list. The conditional list includes corresponding events representing an association of the UI controls and the data objects. Based upon a modification to a data object, an optimized data binding structure is generated to determine a corresponding UI control that is affected by the modification. An updated UI controls list is computed to include the affected one or more UI controls based upon the optimized data binding structure. Based upon a trigger to render the UI area, the affected UIs are regenerated on the UI area by updating the affected UI controls based upon the modification. | 01-16-2014 |
20140019890 | SYNCHRONIZING A USER INTERFACE AREA - A user interface (UI) area having multiple data sources is synchronized based upon changes made to UI elements associated with the UI area. To synchronize the changed UI elements, a processor of the computer determines UI controls and data objects associated with the UI area. Based upon a modification to a data object, a corresponding UI control that is affected by the modification is determined. A synchronization process is triggered to determine updated UI controls and updatable UI controls from the UI controls that are affected by the modification. The UI area is synchronized by updating the updatable UI controls based upon the modification. | 01-16-2014 |
Patent application number | Description | Published |
20150082208 | MULTI-LEVEL USER INTERFACE THEMING - The present disclosure describes methods, systems, and computer program products for providing multi-level user interface theming. One computer-implemented method includes receiving a request to modify an existing theme, receiving a change to a quick theming classified parameter, receiving a change to a base theming classified parameter, receiving a change to an expert theming classified parameter, and publishing the modified theme. | 03-19-2015 |
20150082214 | MULTI-LEVEL USER INTERFACE THEMING ENGINE - The present disclosure describes methods, systems, and computer program products for providing a multi-level user interface theming engine. One computer-implemented method includes initiating a start of a user interface following receipt of a theming request, requesting available themes for presentation in the user interface, receiving a request to access an existing theme, receiving theming data responsive to a generated request to load the existing theme, and receiving a request to publish modified theming data. | 03-19-2015 |